- Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with NUDT15 heterozygosity
-
Maeda T, Sakuraba H, Hiraga H, Yoshida S, Kakuta Y, Kikuchi H, Kawaguchi S, Hasui K, Tatsuta T, Chinda D, Mikami T, Fukuda S
- KMID: 2525076
- Intest Res.
- 2022 Jan;20(1):90-100.
- doi: 10.5217/ir.2020.00133
Background/Aims: Thiopurines are key drugs for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Recently, NUDT15 polymorphism (R139C, c.415C > T) has been shown to be... -
- CITED
-
- Close
- SHARE
-
- Close
- Dynamization–Posterior Lumbar Interbody Fusion for Hemodialysis-Related Spondyloarthropathy: Evaluation of the Radiographic Outcomes and Reoperation Rate within 2 Years Postoperatively
-
Yasukawa T, Ohya J, Kawamura N, Yoshida Y, Onishi Y, Kohata K, Kakuta Y, Nagatani S, Kudo Y, Shirahata T, Kunogi J
- KMID: 2535774
- Asian Spine J.
- 2022 Oct;16(5):684-691.
- doi: 10.31616/asj.2021.0312
Study Design: Clinical case series. Purpose: This study aimed to report dynamization–posterior lumbar interbody fusion (PLIF), our surgical treatment for hemodialysisrelated spondyloarthropathy (HSA), and investigate patients’ postoperative course within 2 years. Overview... -
- CITED
-
- Close
- SHARE
-
- Close
- NUDT15, FTO, and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel diseases
-
Sato T, Takagawa T, Kakuta Y, Nishio A, Kawai M, Kamikozuru K, Yokoyama Y, Kita Y, Miyazaki T, Iimuro M, Hida N, Hori K, Ikeuchi H, Nakamura S
- KMID: 2382376
- Intest Res.
- 2017 Jul;15(3):328-337.
- doi: 10.5217/ir.2017.15.3.328
BACKGROUND/AIMS: Recent genome-wide analyses have provided strong evidence concerning adverse events caused by thiopurine drugs such as azathioprine (AZA) and 6-mercaptopurine. The strong associations identified between NUDT15 p.Arg139Cys and thiopurine-induced... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
-
Moroi R, Endo K, Yamamoto K, Naito T, Onodera M, Kuroha M, Kanazawa Y, Kimura T, Kakuta Y, Masamune A, Kinouchi Y, Shimosegawa T
- KMID: 2438448
- Intest Res.
- 2019 Jan;17(1):94-106.
- doi: 10.5217/ir.2018.00048
BACKGROUND/AIMS: Few reports have described the long-term treatment outcomes of the anti-tumor necrosis factor-α antibody for Japanese Crohn’s disease (CD) patients. The aim of this study was to evaluate them... -
- CITED
-
- Close
- SHARE
-
- Close
